What was the primary driver for the revenue decline in the first quarter of 2009?

The primary driver for the revenue decline was a decrease in the Companion Animal Group (CAG) segment, which was impacted by broader economic conditions affecting veterinary clinic visits and a substantial reduction in pharmaceutical product revenue due to a divestiture completed in late 2008. The Water and Production Animal segments also experienced revenue decreases.

How did the company manage profitability despite the revenue decrease?

IDEXX Laboratories effectively managed profitability through stringent cost controls. Operating expenses were reduced by 5.6%, and despite lower revenues, the overall gross profit margin saw a slight improvement to 52.6% from 52.1% in the prior year, indicating successful operational efficiencies and a favorable shift in product mix within certain segments.

What is the company's financial position and liquidity outlook?

The company maintains a strong liquidity position, ending the quarter with $86.3 million in cash and cash equivalents. It also has $34.5 million in available borrowing capacity under its credit facility. Management believes these resources are sufficient to fund operations, capital expenditures, and strategic growth initiatives, even amidst the challenging economic environment.

What is the impact of the economic downturn on IDEXX's business?

The economic downturn has negatively impacted IDEXX, particularly in the companion animal sector, leading to fewer routine and elective veterinary visits and more cautious spending by veterinarians on capital equipment. The company also noted impacts on non-regulatory water testing volumes. While these trends are expected to continue in the near-term, management believes the fundamental demand drivers remain intact.

IDXX 10-Q Quarterly Report Q1 FY2009 — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. reported a decrease in revenue for the first quarter of 2009 compared to the same period in 2008, primarily driven by the Companion Animal Group (CAG) segment, which saw a 4.5% decline. This revenue drop is attributed to broader economic conditions impacting veterinary visits and cautious spending by veterinarians, as well as a significant reduction in pharmaceutical product revenue following a divestiture in late 2008. Despite the revenue headwinds, the company demonstrated effective cost management, leading to a slight increase in the overall gross profit margin and a modest decrease in operating expenses. Net income for the quarter was $26.1 million, a decrease from $27.6 million in the prior year, with diluted EPS at $0.43, down from $0.43 in Q1 2008, reflecting a slight increase in share count. The company maintained a healthy cash position and positive cash flow from operations, indicating financial resilience amidst challenging economic times. Investors should note the continued impact of the broader economic downturn on the veterinary market, particularly affecting routine and elective procedures. The significant decline in pharmaceutical revenue is a one-time event due to divestiture and should not be considered indicative of ongoing business performance. Management's focus on cost control and operational efficiency is evident, helping to mitigate the impact of reduced sales. The company's liquidity remains strong, with ample cash and available credit, positioning it to navigate the current economic climate.

Key Highlights

1Total revenue decreased by 5.1% to $236.5 million in Q1 2009 compared to $249.1 million in Q1 2008.
2Companion Animal Group (CAG) revenue declined 4.5% to $193.7 million, influenced by economic conditions and a large decrease in pharmaceutical product sales due to divestiture.
3Net income decreased to $26.1 million ($0.43 diluted EPS) from $27.6 million ($0.43 diluted EPS) in the prior year's quarter.
4Gross profit margin improved slightly to 52.6% from 52.1% due to effective cost management and favorable product mix in certain segments.
5Operating expenses decreased by 5.6% to $86.0 million, reflecting successful cost control measures.
6The company ended the quarter with $86.3 million in cash and cash equivalents and $34.5 million in remaining borrowing availability under its credit facility.
7The company repurchased $15.0 million of its common stock during the quarter as part of its ongoing share repurchase program.

IDEXX LABORATORIES INC /DE Quarterly Report for Q1 Ended Mar 31, 2009

Summary

Key Highlights

Frequently Asked Questions